季節性インフルエンザワクチン治療の世界市場：医薬品予測・市場分析（～2025）

2017年3月6日 // 0 Comments

PharmaPoint: Seasonal Influenza Vaccines – Global Drug Forecast and Market Analysis to 2025
Summary

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

Today, available vaccines include the older egg-based, adjuvanted and non- adjuvanted inactivated vaccines, along with live-attenuated vaccines and newer, cell culture-based seasonal influenza vaccines. Within these four vaccine classes, continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. The anticipated launch of quadrivalent, cell culture-based VLP vaccines will have the potential to revolutionize the approaches used to protect against seasonal influenza infections. GlobalData expects the global seasonal influenza vaccines market – which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) – to grow moderately during the next decade at a CAGR of 3.3%, reaching total sales of $4.3 billion by 2025.

Highlights

Key Questions Answered

– Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the seasonal influenza vaccine marketplace.
– What will be the effect of recent and upcoming changes in national immunization schedules?
– How will the upcoming first-in-class Virus-Like Particle (VLP) vaccine be received in the different markets?
– What research and development (R&D) strategies will companies leverage to compete in the future seasonal influenza vaccine marketplace?
– Which patient population(s) are most likely to be targeted by seasonal influenza vaccines?

Key Findings

– GlobalData has calculated that the global seasonal influenza vaccine market generated about $3.1 billion in sales in 2015. This global market is expected to grow modestly at a Compound Annual Growth Rate (CAGR) of 3.3%, reaching sales of $4.3 billion by 2025. The majority of this growth will occur in the 5EU, driven by the uptake of egg-based, quadrivalent vaccines. Further growth is anticipated due to the launch of cell-culture. quadrivalent vaccines in the 7MM. The seasonal influenza vaccines market in the 5EU is expected to grow at a CAGR of 5.5%, reaching sales of $1 billion by 2025. GlobalData estimates sales in the US to grow moderately at a CAGR of 3.5% during the next 10 years, reaching $2.6 billion by 2025, while Japan will experience marginal growth, with a CAGR of 0.3%.
– KOLs interviewed by GlobalData repeatedly identified the effectiveness of seasonal influenza vaccines as the number one unmet need. They argued that the influenza virus rapid antigenic drift coupled to a time-consuming egg-based vaccine manufacturing approach are barriers to increasing vaccine efficacy and duration.
– GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.

Scope

– Overview of seasonal influenza, including epidemiology, etiology, pathophysiology, as well current routine seasonal influenza vaccine recommendations of all 7MM covered.
– Top-line seasonal influenza vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the seasonal influenza vaccine market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
– Analysis of the current and future market competition in the global seasonal influenza vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global seasonal influenza vaccine market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seasonal influenza vaccine market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

統合失調症治療の世界市場：医薬品予測・市場分析（～2025）

2017年3月6日 // 0 Comments

PharmaPoint: Schizophrenia – Global Drug Forecast and Market Analysis to 2025
Summary

Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including attention, memory, and executive functions). A multitude of antipsychotic products are currently available for the pharmacological management of schizophrenia, many of which are already available as inexpensive generics. Further patent and exclusivity losses in key franchises throughout the forecast period will act as a barrier to growth in the 7MM, making the schizophrenia market more competitive and crowded. Growth in the schizophrenia market is expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards significant unmet needs.

Highlights

Key Questions Answered

– The schizophrenia market is widely genericized and many of the unexpired patents are due to expire during the forecast period. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
– There are five substantial unmet needs that exist in the schizophrenia market. Will pipeline drugs fulfil any of the unmet needs for schizophrenia? Which unmet needs will continue to provide opportunity for drug developers during the forecast period?
– Out of the nine late-stage pipeline products, six of these are expected to launch during the forecast period to 2025. What impact will these drugs have on the market? How will they affect the treatment algorithm for schizophrenia?

Key Findings

– The main driver of growth in the schizophrenia market will be the uptake of novel pipeline products, such as Minerva Neuroscience’s MIN-101, Intra-Cellular Therapies’ ITI-007, and Alkermes’ ALKS-3831. The pipeline products are forecast to account for 36.2% of the schizophrenia market by 2025 in the 7MM.
– Several pharma companies have focused on developing long acting injectable (LAI) formulations of their oral brands to tailor treatment plans according to patient’s individual needs and improve patient compliance, which is a notable unmet need. Despite the growing popularity of LAIs, this segment is becoming increasingly competitive with three further late-stage pipeline products expected to be launched during the forecast period.
– There are currently no products approved for the treatment of negative symptoms or cognitive impairments associated with schizophrenia, and only one drug approved for treatment-resistant patients. These constitute the major unmet needs in the schizophrenia market.
– The biggest barrier for growth in the schizophrenia market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.

Scope

– Overview of schizophrenia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized schizophrenia market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
– Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the schizophrenia therapeutics market.
– Pipeline analysis: focus on nine late-stage pipeline schizophrenia drugs, discussing emerging trends as well as an overview of earlier phase drugs.
– Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the global schizophrenia therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global schizophrenia therapeutics market from 2015-2025.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

人工呼吸器・人工蘇生器の世界市場分析・予測

2017年3月6日 // 0 Comments

MediPoint: Respiratory Ventilators and Resuscitators – Global Analysis and Market Forecasts
Summary

Mechanical ventilators dominate the ventilation devices market, due to their effective functionalities and advanced features.

Growth in the respiratory ventilators and resuscitators market will be driven primarily by aging populations, increasing number of ICU admissions, technological innovation, favorable government healthcare policy, and rising popularity of non-invasive ventilators.

The new technologies of ventilators, including closed-loop modes, automated weaning features, and smart alarm systems, continue to improve patient outcomes, ease of use, and efficiency.

Dräger and Maquet are leaders in the market, followed by Medtronic and Hamilton. Other companies include Air Liquide, Ambu, CareFusion, Fisher & Paykel, GE, Philips, ResMed, and Smiths.

Highlights

Key Questions Answered

– What is the current and future respiratory ventilators and resuscitators market outlook in the developed and emerging markets? What trends and events are affecting the global market?
– Which are the key, high growth markets that device manufacturers should expand into? Which markets are growing the fastest, and what are the top-selling products?
– What are the unmet needs with the current generation of devices ? How will emerging technologies such as personalized ventilation fulfill these unmet needs?
– How will regulatory changes affect the market? When are new devices expected to commercialize?
– What are the challenges and complications that have hindered widespread adoption?
– With developing the next-generation of devices, what aspects of the technology are device manufacturers focused on optimizing? How will new entrants impact the global respiratory ventilation devices market?

Key Findings

– Driven by aging populations, an increasing number of ICU admissions, and expanding demand for respiratory devices in emerging countries, the global respiratory ventilators and resuscitators market is expanding at a stable compound annual growth rate (CAGR) of 3.2%.
– Critical care ventilators dominate the market, whereas the markets for neonatal/pediatric ventilators, and transport ventilators are growing steadily.
– The NA is the largest market, owing to a large number of ICU beds and user adoption of new technology. Emerging economies demonstrate stronger growth than global averages.
– Dräger and Maquet became market leaders by offering a variety of products with extensive feature sets. Other companies have remained innovative in order to compete with the larger manufacturers.

Scope

– Competitive assessment: Currently marketed respiratory ventilators and resuscitators and evolving competitive landscape
– In-depth analysis of unmet needs and adoption trends of different respiratory ventilators and resuscitators.
– Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
– Pipeline analysis: Emerging products and technologies.
– Annualized total respiratory ventilators and resuscitators market revenue by segment and market outlooks by country from 2014-2023.
– Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global respiratory ventilators and resuscitators market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global respiratory ventilators and resuscitators market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track device sales in the global and country-specific respiratory ventilators and resuscitators market from 2014-2023.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

うつ病（大うつ病性障害）治療の世界市場：医薬品予測・市場分析（～2025）

2017年3月6日 // 0 Comments

PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025
Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.

Highlights

Key Questions Answered

– The MDD market is widely genericized. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
– There are five substantial unmet needs that exist in the MDD market. Will pipeline drugs fulfil any of the unmet needs for MDD? Which unmet needs will continue to provide opportunity for drug developers during the forecast period?
– Six late-stage pipeline products are expected to launch during the forecast period to 2025. What impact will these drugs have on the market? How will they affect the treatment algorithm for MDD?

Key Findings

– The main drivers of growth in the MDD market will be the uptake of atypical antipsychotic products throughout the 7MM, most notably from Otsuka/Lundbeck’s Rexulti. These agents are forecast to be the highest selling MDD products by 2025, accounting for 38.9% of the MDD market in the 7MM.
– The six late-stage pipeline products are all adjunctive therapies aimed at treating treatment-resistant patients and aim to satisfy major unmet needs within the MDD market; providing therapies with better efficacy, improved safety profiles, and rapid onsets of action.
– The biggest barrier for growth in the MDD market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.
– Growth in the MDD market is also expected to be driven by increasing diagnosed prevalence of MDD, due to increased public awareness and routine screening for depressive disorders, as well as an increase in socioeconomic stress.

Scope

– Overview of MDD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized MDD market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
– Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MDD therapeutics market.
– Pipeline analysis: focus on eight late-stage pipeline MDD drugs, discussing emerging trends as well as an overview of earlier phase drugs.
– Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global MDD therapeutics market from 2015-2025.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

経皮的冠動脈形成術（PCI）の世界市場分析・予測

2017年3月6日 // 0 Comments

MediPoint: Percutaneous Coronary Interventions – Global Analysis and Market Forecasts
Summary

Coronary stents, which include bare metal stents, drug-eluting stents (DESes), covered stents, and bioabsorbable stents (BASes)

De novo stenosis, acute myocardial infarction (AMI), bifurcation lesions, small vessel disease (SVD), saphenous vein grafts (SVGs), left main coronary artery disease (LMCAD), and chronic total occlusions (CTOs)

In the US and 5EU, coronary stents market value is expected to decline slowly, whereas it is expected to demonstrate steady growth in the APAC and South American regions

Newer technologies, such as BASes and the third generation of DESes aim to address unmet needs of complex lesions and challenging populations

The development and commercialization of the next generation of DESes with innovative platforms indicates the continued value of DESes in the coronary market

The coronary stents market is largely dominated by a few key players, including Abbott Vascular, Medtronic, and Boston Scientific

Other key players include B. Braun, Biosensors International, Biotronik, and Terumo as they develop innovative coronary stent platforms.

Highlights

Key Questions Answered

– What is the current and future percutaneous coronary interventions market outlook in the developed and emerging markets? What trends are affecting the global market?
– Which are the key, high growth markets that device manufacturers should expand into? Which markets are growing the fastest, and what are the top-selling products in each segment?
– What are the unmet needs with the current generation of devices? How will emerging technologies such as bioabsorbable stents and drug-eluting stents fulfill these unmet needs?
– What is the physician perception of these new technologies? Which indications have been treated most successfully using minimally invasive treatments?
– What are the challenges and complications that have hindered widespread adoption?
– With developing the next-generation of devices, what aspects of the technology are device manufacturers focused on optimizing? How will new entrants impact the global percutaneous coronary interventions market?

Key Findings

– Growth in the percutaneous coronary interventions market will be driven primarily by rising procedure volumes, the increasing global prevalence of coronary artery disease, and as rising rates of diabetes in particular.
– The introduction of Bioabsorbable stents (BASes) can reduce or even eliminate the prolonged use of DAPT; as long-term clinical efficacy data become available, clinicians will prefer to use BASes over drug-eluting stents (DESes).
– Bioabsorbable stents (BASes) are also expected to see fast adoption as they are introduced across major markets, as they have the potential to significantly reduce restenosis rates and allow for vessel remodeling.
– The current key players will need to retain and acquire market share by improving the clinical performance of their existing products.

Scope

– Overview of percutaneous coronary interventions, including reimbursement trends and M&A analysis
– Annualized total market revenue by type of device, procedure trends, and market outlooks by country through 2022.
– Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in each region covered in the report, and implications of the emerging technologies on the market.
– Pipeline analysis: Comprehensive data split across different stages of development and analysis of emerging trends in design.
– Analysis of the current and future market competition in the global percutaneous coronary interventions market. Insightful review of the key industry drivers, opportunities, barriers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

– The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global percutaneous coronary interventions market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global percutaneous coronary interventions market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track device sales in the global and country-specific peripheral vascular interventions market from 2012-2022.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

銀鉱業の世界市場（～2020）

2017年3月6日 // 0 Comments

Global Silver Mining to 2020
Summary

Global silver metal reserves totaled were 571,000 tones (t) at the end of January 2016. Peru accounted for the largest share, with 21%, followed by Australia and Poland with 14.9% each, Chile with 13.5%, China with 7.5% and with Mexico 6.5%. Peruvian silver deposits are mainly located in the Pasco, Lima, Junin and Apurimac regions. The Toromocho project in Junin, the Cerro de Pasco mine in Pasco and the Las Bambas project in Apurimac contain the country’s main silver deposits.

Scope

– The report contains an overview of the global silver mining industry together with the key factors affecting the industry and demand for the commodity. It also provides information about global silver reserves, the historic and forecast data on silver production, prices, silver metal consumption, the competitive landscape and active, exploration and development silver projects.

Reasons to buy

– Gain an understanding of the global silver mining industry, reserves, historic and forecast data on silver production, prices, silver metal consumption, factors affecting demand for silver, active, exploration and development silver projects and the competitive landscape.

銅鉱業の世界市場（～2020）

2017年3月6日 // 0 Comments

Global Copper Mining to 2020
Summary

Global copper reserves were 720 million tonnes (Mt), with Chile dominating with 210Mt or 29.2% of the total. This was followed by Australia with 88Mt (12.2%), Peru with 82Mt (11.4%) and Mexico with 46Mt (6.4%).

Copper is available in different forms, including sulfide deposits, carbonate deposits and silicate deposits. Porphyry copper deposits are the main source of copper, and approximately 60% of the world’s copper is sourced from these deposits, followed by sediment-hosted stratabound deposits with 20%.

Scope

– The report contains an overview of the global copper mining industry together with the key factors affecting the industry and demand for the commodity.
– It also provides information about global copper reserves, the historic and forecast data on copper production, prices, copper metal consumption, the competitive landscape and active, exploration and development copper projects.

Reasons to buy

– Gain an understanding of the global copper mining industry, reserves, historic and forecast data on copper production, prices, copper metal consumption, demand drivers, active, exploration and development copper projects and the competitive landscape.

石炭鉱業の世界市場（～2020）

2017年3月6日 // 0 Comments

Global Coal Mining to 2020
Summary

Global coal reserves totaled 891.5 billion tonnes (Bnt) at the end of 2015. Sub-bituminous and lignite coal accounted for 54.8%, or 488.3bnt, while anthracite and bituminous coal collectively accounted for 45.2%, or 403.2Bnt.

The US ranked first in terms of coal reserves, with a global share of 26.6% or 237.3Bnt in 2015, followed by Russia with 157.0Bnt, China with 114.5Bnt, Australia with 76.4Bnt, India with 60.6Bnt and Germany with 40.5Bnt.

Scope

– The report contains an overview of the global coal mining industry together with the key factors affecting the industry and demand for the commodity.
– It also provides information about global coal reserves, the historic and forecast data on coal production, prices, coal consumption, the competitive landscape and active, exploration and development coal projects.

Reasons to buy

– Gain an understanding of the global coal mining industry, reserves, historic and forecast data on coal production, prices, coal consumption, demand drivers, active, exploration and development coal projects and the competitive landscape.

金鉱業の世界市場（～2020）

2017年3月6日 // 0 Comments

Global Gold Mining to 2020
Summary

Global gold reserves were 56,700 tonnes (t) as of January 2016, with Australia accounting for the largest share with 9,100t or 16% of the total, followed by Russia with 8,000t (14.1%), South Africa with 6,000t (10.6%), the US and Indonesia each with 3,000t (5.3%), Peru with 2,800t (4.9%), Brazil with 2,400t (4.2%) and the remainder by other countries.

Gold reserves in Russia are mostly located in the Far East and Krasnoyarsk districts. The Witwatersrand basin remains the largest gold deposit basin in South Africa.

Scope

– The report contains an overview of the global gold mining industry together with the key factors affecting the industry and demand for the commodity.
– It also provides information about global gold reserves, the historic and forecast data on gold production, prices, gold metal consumption, the competitive landscape and active, exploration and development gold projects.

Reasons to buy

– Gain an understanding of the global gold mining industry, reserves, historic and forecast data on gold production, prices, gold metal consumption, demand drivers, active, exploration and development gold projects and the competitive landscape.

亜鉛鉱業の世界市場（～2020）

2017年3月6日 // 0 Comments

Global Zinc Mining to 2020
Summary

Australia, China, Peru, Mexico and the US have the largest zinc reserves and together accounted for 152 million tonnes (Mt), or 74.5% of the global total as of January 2016, although zinc ore deposits are found in more than 50 countries.

More than 30% of Australia’s zinc reserves are collectively located in Queensland, New South Wales and Western Australia, with smaller deposits in Tasmania and the Northern Territory. China’s Yunnan province accounts for 22.8% of the country’s total zinc reserves, followed by Inner Mongolia with 19.3%, Gansu with 10.7%, Guangdong with 8.15%, Sichuan with 6.95%, and Qinghai with 4.8%.

The global zinc mining industry has recorded steady growth since 2010, supported by demand from the construction and automobile sectors. In 2015, global zinc mine production was an estimated 13.4Mt in 2015, up by 0.4% over 2014 as a result of an increase in production from Australia, India and Peru.

Scope

– The report contains an overview of the global zinc mining industry together with the key factors affecting the industry and demand for the commodity.
– It also provides information about global zinc reserves, the historic and forecast data on zinc production, prices and zinc smelters by major companies, refined zinc consumption, the competitive landscape and active, exploration and development zinc projects.

Reasons to buy

– Gain an understanding of the global zinc mining industry, reserves, historic and forecast data on zinc production, prices, zinc smelters by major companies, refined zinc consumption, demand drivers, active, exploration and development zinc projects and the competitive landscape.

ボーキサイト（鉄礬土）鉱業の世界市場（～2020）

2017年3月6日 // 0 Comments

Global Bauxite Mining to 2020
Summary

Global bauxite reserves were 27.5 billion tonnes (Bnt) as of January 2016. Guinea had the world’s largest reserves, with 7.4Bnt, accounting for 26.9% of the global total, with most bauxite deposits located in the western and central part of the country. Australia held the second largest reserves at 6.2Bnt. The highest grade bauxite reserves are located in Queensland and the Northern Territory, with the Weipa and Gove mines having grades of 49-53% Al2O3. Brazil ranked third with 2.6Bnt of bauxite reserves, of which around 80% are located in the Trombetas region.

Global bauxite ore production was an estimated 279.7 million tonnes (Mt) in 2015, a decrease of 0.3% over the previous year, as a result of a decline in production from Brazilian and Chinese bauxite ore mines. Global bauxite production in 2014 at 280.6Mt was also, down by 5.2% over 2013 due to a fall in production from Indonesia. The country produced just 500kt in 2014, against 55.7Mt in 2013, as a result of the ban on exports of raw ores imposed at the beginning of 2014.

Scope

– The report contains an overview of the global bauxite mining industry together with the key factors affecting the industry and demand for the commodity.
– It also provides information about global bauxite reserves, historic and forecast data on bauxite production, data on major bauxite ores and concentrates exporting and importing countries, the competitive landscape and active, exploration and development bauxite projects.

Reasons to buy

– Gain an understanding of the global bauxite mining industry, reserves, historic and forecast data on bauxite production, aluminium prices, trade data for major exporting and importing countries, demand drivers, active, exploration and development bauxite projects and the competitive landscape.

鉄鉱石鉱業の世界市場（～2020）

2017年3月6日 // 0 Comments

Global Iron Ore Mining to 2020
Summary

Global iron ore reserves were 185.1 billion tonnes (Bnt) as of January 2016, with Australia accounting for the largest share with 54Bnt or 29.2% of the total, followed by Russia with 25Bnt (13.5%), Brazil and China with 23Bnt each (12.4%), the US with 11.5Bnt (6.2%) and India with 8.1Bnt (4.4%).

In Australia, more than 90% of the total reserves are located in the Pilbara region of Western Australia, with smaller amounts in South Australia, New South Wales, Queensland and Tasmania. Reserves of both hematite and magnetite ores are available with average Fe grade of 59.6%.

In Russia, the Ural region, Moscow (Tula region), North West Russia and Siberia have the country’s largest iron ore deposits. The best grade deposits are found in the Ural region, while the Tula region, also known as the Kursk Magnetic Anomaly (KMA), has reserves with average iron content in the range of 34-39%.

Scope

– The report contains an overview of the global iron ore mining industry together with the key factors affecting the industry and demand for the commodity.
– It also provides information about global iron ore reserves, historic and forecast data on iron ore production and consumption, data on major iron ores and concentrates exporting and importing countries, the competitive landscape and active, exploration and development iron ore projects.

Reasons to buy

– Gain an understanding of the global iron ore mining industry, iron ore reserves, historic and forecast data on iron ore production, iron ore prices and consumption, trade data for major exporting and importing countries, demand drivers, active, exploration and development iron ore projects and the competitive landscape.

ウラン鉱業の世界市場（～2020）

2017年3月6日 // 0 Comments

Global Uranium Mining to 2020
Summary

Global uranium mine production according to GlobalData’s global uranium report was 56,184 tonnes (t) in 2014, down by 5.4% compared with 2013, with Kazakhstan being the leading producer, followed by Canada and Australia.

Scope

– The report provides information on the global uranium mining industry together with the key demand drivers affecting the industry. Further, it provides information about reserves, historic and forecast production and production by country, production by mining method and production by major mines, competitive landscape and major active, exploration and development projects.

Reasons to buy

– Gain an understanding of the global uranium mining industry, the relevant demand drivers , reserves, historic and forecast production, production by major country, production by mining method and production by major mines, active, exploration and development projects and the competitive landscape.

白金鉱業の世界市場（～2020）

2017年3月6日 // 0 Comments

Global Platinum Mining to 2020
Summary

Global PGM reserves according to GlobalData’s global platinum report was 2.4 billion ounces in January 2015, with South Africa accounting for 91.4% of this total, followed by Zimbabwe, Russia and the US with 4.1%, 1.6% and 1.3% respectively. The Bushveld Igneous Complex in South Africa and the Great Dyke Mineral belt in Zimbabwe are two of the world’s largest sources of platinum.

Scope

– The report provides information on the global platinum mining industry together with the key demand drivers affecting the industry. Further, it provides information about reserves, historic and forecast production and production by country, the competitive landscape and major active, exploration and development projects.

Reasons to buy

– Gain an understanding of the global platinum mining industry, the relevant demand drivers , reserves, historic and forecast production, production by major country, active, exploration and development projects and the competitive landscape.